Free Communications - Screening 2: New screening strategies – country experiences

5:45 PM • FC 06-01 • Current status of cervical cancer screening programs and HPV vaccination in southeast European countries > M. Mario POLJAK 5:53 PM • FC 06-02 • Screening outcome after HPV-vaccination in Denmark > E. Elsebeth Lynge 6:01 PM • FC 06-03 • Five-year risk of cervical precancer following p16/KI-67 dual stain triage of HPV-positive women > M. Megan Clarke 6:09 PM • FC 06-04 • Sensitivity and positive predictive value of HPV E6/E7 mRNA overexpression assay as triage test for HPV positive women > P. Paolo GIORGI ROSSI 6:17 PM • FC 06-05 • Cytological triage and molecular triage with partial genotyping in HPV primary screening: comparison of data from an Italian Region (Tuscany) > F. Francesca Carozzi 6:25 PM • FC 06-06 • HPV as the primary screening test for cervical cancer: initial results from a Danish implementation study > M. Marianne Waldstrom 6:33 PM • FC 06-07 • Primary HPV DNA screening: two years experience after 5y of co-testing > R. Rosa Oncins 6:41 PM • FC 06-08 • 16/18 genotyping of persistent HR-HPV infections with negative cytology: results from the English cervical screening pilot > M. Matejka Rebolj 6:49 PM • FC 06-09 • HPV focal 48 month exit survey: women’s real world experiences surrounding primary HPV testing > L. Laurie Smith 6:57 PM • FC 06-10 • Cancer cases identified in a randomized implementation of HPV-screening in the Norwegian cervical cancer screening programme > B. Birgit Engesæter 7:05 PM • FC 06-11 • First results of high-risk HPV screening in the cervical cancer screening programme in the Netherlands: participation, referral and detection > C. Clare Aitken 7:13 PM • FC 06-12 • The longitudinal clinical performance of the RNA-based Aptima Human Papillomavirus (HPV) Assay in comparison to the DNA-based Hybrid Capture 2 HPV Test in 2 consecutive screening rounds with a 6-year interval in a Routine Screening Population of 10.000 women in Germany > T. Thomas IFTNER 7:21 PM • FC 06-13 • Risks of CIN3+ by cytology and human papilloma virus genotype: a risk-based approach to cervical cancer screening in Norway > A. Ameli TROPÉ 7:29 PM • FC 06-14 • Development of evidence-based guidelines for follow up of women treated for cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) in Italian screening programs > F. Francesco Venturelli 7:37 PM • FC 06-15 • A 5-year follow-up study of the diagnostic efficacy using primary hrHPV testing vs. liquid based cytology in cervical cancer screening of women aged 50+ > B. Berit Andersen